Pre-made Bermekimab benchmark antibody ( Whole mAb, anti-IL1A therapeutic antibody, Anti-IL1/IL-1A/IL1F1/IL1-ALPHA/IL-1 alpha Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Bermekimab biosimilar, Whole mAb, Anti-IL1A Antibody: Anti-IL1/IL-1A/IL1F1/IL1-ALPHA/IL-1 alpha therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Bermekimab[1] (MABp1, trade name Xilonix) is a human monoclonal antibody of IgG1k isotype targeting Interleukin 1 alpha (IL1A). As of March 2017, bermekimab is in phase III clinical trials as an immunotherapy for colorectal cancer and as of September 2018 in phase II clinical trials for the treatment of atopic dermatitis.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-063-1mg	1mg	3090	30%	2163

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Bermekimab biosimilar, Whole mAb, Anti-IL1A Antibody: Anti-IL1/IL-1A/IL1F1/IL1-ALPHA/IL-1 alpha therapeutic antibody
INN Name	Bermekimab
Target	IL1A
Format	Whole mAb
Derivation
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Preregistration
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2018
Year Recommended	2019
Companies	XBiotech Inc.
Conditions Approved	na
Conditions Active	Colorectal cancer;Cachexia;Atopic dermatitis;Acne vulgaris;Hidradenitis suppurativa;Non-small cell lung cancer;Plaque psoriasis;Systemic scleroderma;Type 2 diabetes mellitus;Vascular restenosis;Pancreatic cancer
Conditions Discontinued	Haematological malignancies
Development Tech	na